JP2022545835A5 - - Google Patents
Info
- Publication number
- JP2022545835A5 JP2022545835A5 JP2022513569A JP2022513569A JP2022545835A5 JP 2022545835 A5 JP2022545835 A5 JP 2022545835A5 JP 2022513569 A JP2022513569 A JP 2022513569A JP 2022513569 A JP2022513569 A JP 2022513569A JP 2022545835 A5 JP2022545835 A5 JP 2022545835A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- ted
- igf
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025101359A JP2025146837A (ja) | 2019-08-28 | 2025-06-17 | 甲状腺眼症の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962892849P | 2019-08-28 | 2019-08-28 | |
| US62/892,849 | 2019-08-28 | ||
| PCT/US2020/048350 WO2021041773A1 (en) | 2019-08-28 | 2020-08-28 | Methods for the treatment of thyroid eye disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101359A Division JP2025146837A (ja) | 2019-08-28 | 2025-06-17 | 甲状腺眼症の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022545835A JP2022545835A (ja) | 2022-10-31 |
| JP2022545835A5 true JP2022545835A5 (enExample) | 2023-09-05 |
Family
ID=74686009
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513569A Pending JP2022545835A (ja) | 2019-08-28 | 2020-08-28 | 甲状腺眼症の治療方法 |
| JP2025101359A Pending JP2025146837A (ja) | 2019-08-28 | 2025-06-17 | 甲状腺眼症の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101359A Pending JP2025146837A (ja) | 2019-08-28 | 2025-06-17 | 甲状腺眼症の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210253719A1 (enExample) |
| EP (1) | EP4021500A4 (enExample) |
| JP (2) | JP2022545835A (enExample) |
| CN (1) | CN115175701A (enExample) |
| AU (1) | AU2020337958A1 (enExample) |
| BR (1) | BR112022003663A2 (enExample) |
| CA (1) | CA3152740A1 (enExample) |
| CO (1) | CO2022003582A2 (enExample) |
| WO (1) | WO2021041773A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016022066A1 (en) | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| AU2018385766B2 (en) | 2017-12-15 | 2022-12-01 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
| WO2019173352A1 (en) | 2018-03-05 | 2019-09-12 | Hznp Limited | Methods for the treatment of thyroid eye disease |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| AU2020337958A1 (en) | 2019-08-28 | 2022-03-17 | Horizon Therapeutics Ireland Dac | Methods for the treatment of thyroid eye disease |
| CN113512116B (zh) * | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | 一种抗igf-1r抗体及其应用 |
| US20220267450A1 (en) | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| CN113143928A (zh) * | 2021-04-02 | 2021-07-23 | 苏州普乐康医药科技有限公司 | 一种osi-906的应用 |
| EP4384219A4 (en) * | 2021-08-10 | 2025-06-18 | Viridian Therapeutics, Inc. | COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE |
| EP4395823A4 (en) * | 2021-09-03 | 2025-07-16 | Novarock Biotherapeutics Ltd | BISPECIFIC BINDING PROTEINS THAT BIND TO CD137 AND A TUMOR-ASSOCIATED ANTIGEN |
| CA3256642A1 (en) * | 2022-05-26 | 2023-11-30 | Horizon Therapeutics Ireland Dac | Methods and compositions for treatment of thyroid eye disease |
| WO2024069236A1 (en) * | 2022-09-30 | 2024-04-04 | Horizon Therapeutics Ireland Dac | Methods for treating inactive or chronic thyroid eye disease |
| AU2024287547A1 (en) * | 2023-07-07 | 2026-01-22 | Viridian Therapeutics, Inc. | Methods of treating chronic thyroid eye disease |
| TW202517640A (zh) * | 2023-07-18 | 2025-05-01 | 愛爾蘭商赫瑞森治療學愛爾蘭指定活動公司 | 用於治療疾病之ｉｇｆ－１ｒ的雜環抑制劑 |
| WO2025051229A1 (zh) | 2023-09-08 | 2025-03-13 | 北京拓界生物医药科技有限公司 | Igf-1r及tshr结合蛋白及其医药用途 |
| WO2025155888A1 (en) * | 2024-01-19 | 2025-07-24 | Sling Therapeutics, Inc. | Use of inhibitors of insulin-like growth factor receptor-1 for ocular-associated disorders |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2373192A (en) | 1943-03-13 | 1945-04-10 | Walter M Lauer | Antioxidants |
| US4567253A (en) | 1984-02-03 | 1986-01-28 | Tony Durst | 2-Substituted derivatives of podophyllotoxin and etoposide |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| US8153121B2 (en) | 2000-10-06 | 2012-04-10 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders |
| US8178304B2 (en) | 2000-10-06 | 2012-05-15 | Smith Terry J | Diagnostic methods relating to Graves' disease and other autoimmune disorders |
| ME00502B (me) | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antitjela za insulinu sličan receptor faktora i rasta |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| CA2524305C (en) | 2003-05-01 | 2015-12-08 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| WO2005058967A2 (en) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
| EP2168968B1 (en) | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| FR2873699B1 (fr) * | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| ES2426482T3 (es) | 2005-01-27 | 2013-10-23 | Kyowa Hakko Kirin Co., Ltd. | Inhibidor de IGF-1R |
| DK1979001T3 (da) | 2005-12-13 | 2012-07-16 | Medimmune Ltd | Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf |
| ES2545907T3 (es) | 2005-12-29 | 2015-09-16 | Abbvie Inc. | Inhibidores de proteína quinasa |
| AU2007245164A1 (en) | 2006-03-28 | 2007-11-08 | Biogen Idec Ma Inc. | Anti-IGF-IR antibodies and uses thereof |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| HRP20140688T1 (hr) | 2006-07-07 | 2014-10-24 | Bristol-Myers Squibb Company | Inhibitori piroltriazin kinaze |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| JP2010506941A (ja) | 2006-10-17 | 2010-03-04 | リセラ，インク． | 甲状腺眼症の治療のための方法、組成物及び製剤 |
| CN101932580B (zh) | 2007-06-01 | 2013-05-22 | 葛兰素史密丝克莱恩有限责任公司 | 咪唑并吡啶激酶抑制剂 |
| ES2424977T3 (es) | 2007-08-08 | 2013-10-10 | Glaxosmithkline Intellectual Property Development Limited | Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer |
| CA2697612A1 (en) * | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-igf-1r antibodies and uses thereof |
| TW201211036A (en) | 2010-06-17 | 2012-03-16 | Kyowa Hakko Kirin Co Ltd | Useful salts of indazole derivative |
| MX2013000617A (es) | 2010-07-16 | 2013-06-13 | Piramal Entpr Ltd | Derivados sustituidos de imidazoquinolina como inhibidores de quinasa. |
| UY33539A (es) | 2010-08-02 | 2012-02-29 | Astrazeneca Ab | Compuestos químicos alk |
| US8546443B2 (en) | 2010-12-21 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Benzylic oxindole pyrimidines |
| US8476409B2 (en) | 2011-04-19 | 2013-07-02 | Merrimack Pharmaceuticals, Inc. | Bispecific anti-IGF-1R and anti-ErbB3 antibodies |
| AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| WO2013110585A1 (en) | 2012-01-23 | 2013-08-01 | Boehringer Ingelheim International Gmbh | 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| WO2016064716A1 (en) | 2014-10-20 | 2016-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination therapy of tshr antagonist and igfr inhibitor |
| JP6664414B2 (ja) | 2015-05-13 | 2020-03-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＩＧＦ−１Ｒ／ＩＲ阻害薬としての新規５，８−ジメチル−９−フェニル−５，８−ジヒドロ−６Ｈ−ピラゾロ［３，４−ｈ］キナゾリン−２−イル）−（１Ｈ−ピラゾール−３−イル）−アミン及び誘導体 |
| US20210284741A1 (en) * | 2018-01-24 | 2021-09-16 | Hznp Limited | Methods for the treatment of thyroid eye disease |
| US11208489B2 (en) * | 2018-01-24 | 2021-12-28 | Horizon Therapeutics Ireland Dac | Methods for the treatment of thyroid eye disease |
| US10457740B1 (en) * | 2018-01-29 | 2019-10-29 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating cancer using P2RX2 inhibitors |
| WO2019173352A1 (en) | 2018-03-05 | 2019-09-12 | Hznp Limited | Methods for the treatment of thyroid eye disease |
| AU2020337958A1 (en) | 2019-08-28 | 2022-03-17 | Horizon Therapeutics Ireland Dac | Methods for the treatment of thyroid eye disease |
-
2020
- 2020-08-28 AU AU2020337958A patent/AU2020337958A1/en active Pending
- 2020-08-28 WO PCT/US2020/048350 patent/WO2021041773A1/en not_active Ceased
- 2020-08-28 CA CA3152740A patent/CA3152740A1/en active Pending
- 2020-08-28 JP JP2022513569A patent/JP2022545835A/ja active Pending
- 2020-08-28 EP EP20858844.2A patent/EP4021500A4/en active Pending
- 2020-08-28 BR BR112022003663A patent/BR112022003663A2/pt unknown
- 2020-08-28 CN CN202080074509.4A patent/CN115175701A/zh active Pending
-
2021
- 2021-03-03 US US17/191,651 patent/US20210253719A1/en not_active Abandoned
-
2022
- 2022-03-10 US US17/654,318 patent/US12600787B2/en active Active
- 2022-03-25 CO CONC2022/0003582A patent/CO2022003582A2/es unknown
-
2025
- 2025-06-17 JP JP2025101359A patent/JP2025146837A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022545835A5 (enExample) | ||
| CN1191859C (zh) | 用于治疗癌症的泰素帝和重组人源化her2单克隆抗体的组合 | |
| JP2023002662A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| IL178745A (en) | Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma | |
| TW202327597A (zh) | 一種ezh2抑制劑用於製備治療t細胞淋巴瘤的藥物的用途 | |
| JP2007515469A5 (enExample) | ||
| WO2019096194A1 (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2017031160A5 (enExample) | ||
| US20140275237A1 (en) | Beraprost isomer as an agent for the treatment of viral infection | |
| JP2015526458A5 (enExample) | ||
| JP2024540183A5 (enExample) | ||
| IL300151A (en) | Combinations for cancer treatment | |
| JP2023530316A5 (enExample) | ||
| CA3188345A1 (en) | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease | |
| JP2018531273A5 (enExample) | ||
| JP2016528240A (ja) | ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬 | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2015517523A5 (enExample) | ||
| CN111727059A (zh) | 包含至少一种剪接体调控剂和至少一种选自BCL2抑制剂、BCL2/BCLxL抑制剂和BCLxL抑制剂的抑制剂的组合及其使用方法 | |
| RU2494736C2 (ru) | Комбинация, включающая паклитаксел, для лечения рака яичников | |
| JP2019529467A5 (enExample) | ||
| CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
| JP2019534251A5 (enExample) | ||
| JP2024525164A5 (enExample) |